Brief: Marker Therapeutics Awarded $2 Million Grant From U.S. FDA To Support Marker’S Phase 2 Artemis Trial Of MT-401 In Post-Transplant Aml

Marker Therapeutics

13/09/2022 12:03

Sept 13 (Reuters) - Marker Therapeutics Inc  MRKR.O :
    * MARKER THERAPEUTICS AWARDED $2 MILLION GRANT FROM U.S. FDA
TO
SUPPORT MARKER’S PHASE 2 ARTEMIS TRIAL OF MT-401 IN
POST-TRANSPLANT AML

Source text for Eikon:  ID:nGNXbVmjss 
Further company coverage:  MRKR.O 

 ((Reuters.Briefs@thomsonreuters.com;))